The Animal Generic Drug User Fee Act
of 2008 (AGDUFA) (Title II of Public Law 110-316 signed by the
President on August 14,2008), authorizes FDA to collect user fees
for certain abbreviated applications for a generic new animal drug,
on certain generic new animal drug products, and on certain
sponsors of such abbreviated applications for generic new animal
drugs and/or investigational submissions for generic new animal
drugs. A generic animal drug application submitted by a person
subject to application fees is considered incomplete and will not
be accepted for filing by FDA until all fees owed by such person
has been paid. AGDUFA requires the submission of the user fees
concurrently with applications. If the required fees are not
submitted, the review of the application will not begin. The "User
Fee Cover Sheet" provides the information to either initiate or
defer the application review.
Must implement program
change by beginning of fiscal year (October 1, 2013), and in
advance of regularly scheduled revision request.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.